Brexpiprazole as an adjunct therapy for cognitive dysfunction in schizophrenia
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-May-2026 02:15 ET (23-May-2026 06:15 GMT/UTC)
Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, affecting social life of patients. However, no effective treatment has yet been established for it. Now, researchers have investigated the effect of adding brexpiprazole on cognitive function in patients with schizophrenia. The findings revealed that patients with schizophrenia receiving adjunctive brexpiprazole showed a meaningful improvement in information processing speed, without worsening psychiatric symptoms.
A new IIASA-led study examines growing critiques of how global climate mitigation scenarios address equity and justice and identifies key conditions for fair, feasible, and politically credible climate action.
A new paper in Nicotine and Tobacco Research finds that people experiencing more economic disadvantages are more likely to smoke cigarettes, have higher levels of tobacco addiction, and find it harder to quit than those who are most advantaged. This pattern was consistent across different forms and severity of disadvantage.